Adverse drug reactions (ADRs) are one of the major causes of morbidity and mortality
worldwide. It is well-known that individual genetic make-up is one of the causative factors of …

Efavirenz is a highly effective HIV-1 antiretroviral; however, it is also frequently associated
with neuropsychiatric adverse events (NPAE) that include abnormal dreams, sleep …

Background We previously reported that integrating antiretroviral therapy (ART) with
tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during …

Background: Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the
standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of …

Background Implication of pharmacogenetic variations and efavirenz pharmacokinetics in
concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury …

Background HIV infection, anti-tuberculosis and efavirenz therapy are associated with
neuropsychological effects. We evaluated the influence of rifampicin cotreatment, efavirenz …

Aims Genetic factors, notably CYP2B6 516G→ T [rs3745274] and 983T→ C [rs28399499],
explain much of the interindividual variability in efavirenz pharmacokinetics, but data from …

ART improves survival in co-infected TB patients, but is complicated by several management
challenges that compromise programmatic implementation in resource-limited settings …

Tuberculosis (TB) and HIV continue to be two of the major causes of morbidity and mortality
in the world, and together are responsible for the death of millions of people every year …

The HIV-associated tuberculosis (TB) epidemic remains a huge challenge to public health in
resource-limited settings. Reducing the nearly 0.5 million deaths that result each year has …